Participants 123 156 4
patients with chronic hepatitis C
Participants 194 268 5
Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial
Participants 340 408 5
patients with chronic hepatitis C and advanced fibrosis or cirrhosis
Participants 604 723 6
517 HALT-C patients received peginterferon alfa-2a (90 microg/week); 532 received no additional treatment for 3.5 years
Participants 944 977 4
Patients with cirrhosis (n = 427)
Participants 1046 1078 4
patients with fibrosis (n = 622)
